pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
Ophthalmology · news · pharmadog
← back to Ophthalmology
News · Ophthalmology
168
stories
12h
Regeneron to challenge Ipsen as FDA clears bone disease drug
biopharma dive
15h
Contrasting legal decisions on gender-affirming care
stat
20h
Opinion: The global health aid architecture is collapsing. The faith economy isn’t
stat
1d
STAT+: In wake of boy’s death, gene editing experts dissect Huidagene’s decisions
stat
1d
Leadership Lab: The one person executives need by their side
biospace
2d
Merck, Moderna’s personalized cancer vaccine slows recurrence in phase 3, setting up approval push
fiercebiotech
2d
STAT+: Nonprofit health system raked in $1.1 billion this year from stake in medical billing firm
stat
2d
STAT+: Real-world psilocybin data suggest need for close monitoring
stat
2d
STAT+: Pharmalittle: We’re reading about a setback for Eyepoint, a win for Amylyx, and more
stat
2d
STAT+: Prominent AI startup rolls out virtual cell model in race to speed up science
stat
2d
Regeneron ends eye disease study due to antibody's safety profile
biospace
2d
Regeneron ends eye disease study due to antibody's safety profile
biospace
2d
STAT+: Amylyx endocrine drug succeeds in pivotal study
stat
2d
STAT+: A pill that mimics exercise? Early results on drug designed to maintain both weight loss and muscle mass
stat
2d
STAT+: Doritos as farm-to-table snacks? Big Food, under duress, gets creative
stat
3d
UPDATED: Oma's Pride Voluntarily Recalls One Lot of Woof Complete Canine Chicken Recipe (6 Lb Bag) Because of Possible Salmonella Health Risk
fda recalls
3d
STAT+: Sanofi to lay off 229 workers in Mass., a year after $9.1B Blueprint Medicines acquisition
stat
3d
STAT+: Eyepoint study results for vision treatment disappoint, but company still sees promise
stat
3d
EyePoint’s bid to compete with Eylea falls flat
endpoints
3d
EyePoint plummets on pivotal data for main drug
biopharma dive
3d
EyePoint’s Phase 3 fail sends stock spiraling amid next-gen AMD race
biospace
3d
Regeneron ends eye disease trial for anti-CD3 antibody following safety review
fiercebiotech
3d
How AI-enabled Software as Medical Devices are Reshaping Regulatory Routes and Medicine
biospace
6d
Skye and Redx form new entity with $125M to advance fibrosis assets
fiercebiotech
6d
‘We’re not afraid of competition’: BioCryst CEO sets out strategy after scrapping internal discovery
fiercebiotech
6d
Opinion: U.S., U.K. health care systems share a fatal flaw
stat
6d
Opinion: MAHA and insurance companies both want to treat human bodies like cars
stat
8d
Oma's Pride Voluntarily Recalls One Lot of Woof Complete Canine Chicken Recipe (6 Lb Bag) Because of Possible Salmonella Health Risk
fda recalls
8d
Pfizer’s former chemistry whiz debuts Khartis Therapeutics with $95M for thyroid eye disease pill
fiercebiotech
8d
With tech backing, AI biotechs force biopharma into ‘fail-fast’ drug development
biospace
← prev
page 1 of 6
next →
